[ABBV] AbbVie Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 62.32 Change: 0.67 (1.08%)
Ext. hours: 62.4 Change: 0.08 (0.13%)

chart ABBV

Refresh chart

Strongest Trends Summary For ABBV

ABBV is in the long-term up 243% in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated

Fundamental Ratios
Shares Outstanding EPS4 EPS Growth - 4 Quarters-44.47% EPS Growth - Q/Q-115.9%
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.31% Sales Growth - Q/Q-7.56% P/E17.76
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.8% ROE131.88% ROI11.6%
Current Ratio1.39 Quick Ratio1.3 Long Term Debt/Equity2.45 Debt Ratio8.02
Gross Margin79.12% Operating Margin18.33% Net Profit Margin8.89% Dividend Payout Ratio-154.52%
Dividend Yield
Fundamental Data
Cash From Financing Activities-930 M Cash From Investing Activities-873 M Cash From Operating Activities1.59 B Gross Profit4.58 B
Net Profit1.37 B Operating Profit2.11 B Total Assets26.7 B Total Current Assets15.41 B
Total Current Liabilities11.05 B Total Debt15.27 B Total Liabilities25.32 B Total Revenue5.48 B
Technical Data
High 52 week121.94 Low 52 week64.52 Last close99.98 Last change0.75%
RSI36.24 Average true range2.28 Beta1.14 Volume4.37 M
Simple moving average 20 days-2.68% Simple moving average 50 days2.42% Simple moving average 200 days2.97%
Performance Data
Performance Week-2.94% Performance Month0.35% Performance Quart-11.94% Performance Half6.85%
Performance Year50.73% Performance Year-to-date5.21% Volatility daily1.66% Volatility weekly3.7%
Volatility monthly7.59% Volatility yearly26.29% Relative Volume229.33% Average Volume8.94 M
New High New Low


2019-12-11 15:32:08 | Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019

2019-12-11 14:42:07 | Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

2019-12-11 14:15:07 | Top Research Reports for Novartis, AbbVie & Sanofi

2019-12-10 10:10:03 | Biotech ETFs Hit New Highs on Deal Activities

2019-12-09 17:45:10 | AbbVie ABBV Dips More Than Broader Markets: What You Should Know

2019-12-09 10:03:27 | World's largest biotech company to move up to BioMed's big South City project

2019-12-09 09:42:02 | J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH

2019-12-09 09:28:02 | Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio

2019-12-09 09:22:02 | 3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019

2019-12-09 08:00:10 | Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay

2019-12-09 08:00:00 | AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics

2019-12-08 07:30:00 | New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® venetoclax Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia CLL

2019-12-07 09:00:00 | More than Seven-Year Analysis of Early Treatment with IMBRUVICA® ibrutinib Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma MCL that Relapsed or Were Unresponsive to Prior Regimen

2019-12-07 07:33:00 | Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® ibrutinib in the Treatment of Chronic Lymphocytic Leukemia CLL

2019-12-07 07:30:00 | IMBRUVICA® ibrutinib Plus VENCLEXTA®/VENCLYXTO® venetoclax Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia CLL

2019-12-06 16:30:10 | Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease CTAD Meeting

2019-12-06 07:27:11 | Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

2019-12-06 06:00:00 | AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance pCPA for SKYRIZI™ risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis

2019-12-05 10:57:37 | Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?

2019-12-05 09:07:02 | J&J Stock Witnesses Volatility in '19: What to Expect in 2020

2019-12-03 09:26:27 | Where to Buy Booming Biotech ETFs

2019-12-03 05:06:00 | [video]AbbVie Affirmed Overweight at Piper Jaffray on Potential of Arthritis Drug

2019-12-02 17:45:10 | AbbVie ABBV Stock Moves -0.79%: What You Should Know

2019-12-02 14:29:00 | Disney Stock Is Loved by Wall Street. Its Bonds? Not So Much.

2019-12-02 09:18:02 | 3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income - December 02, 2019

2019-12-01 09:30:02 | AbbVie ABBV Up 10.3% Since Last Earnings Report: Can It Continue?

2019-11-30 17:14:16 | Did Hedge Funds Drop The Ball On AbbVie Inc ABBV ?

2019-11-29 09:15:02 | Market Serves Up More Records for Thanksgiving

2019-11-27 23:22:16 | Why some corporate bond investors see higher risk in higher ratings

2019-11-27 19:06:12 | 3 Stocks for Value Investors to Buy as Market Reaches New High

2019-11-27 12:33:04 | Johnson Adviser Warns of Chance of Hung Parliament: U.K. Votes

2019-11-27 11:02:00 | Tory Prime Minister Johnson has held secret talks with U.S. about privatizing National Health Service, Labour rival claims

2019-11-26 17:54:52 | BeiGene Shares Climb Nearly 50% After Amgen Deal

2019-11-26 09:20:02 | 3 Top Dividend Stocks to Maximize Your Retirement Income - November 26, 2019

2019-11-25 09:37:16 | Timing the Market, Is it Possible? - November 25, 2019

2019-11-22 10:57:03 | Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes

2019-11-22 10:08:01 | AstraZeneca shares rise on early U.S. approval for leukemia drug

2019-11-21 08:30:00 | AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting

2019-11-21 04:00:00 | Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

2019-11-20 09:55:44 | Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - November 20, 2019

2019-11-20 09:22:02 | Myovant Up on Successful Completion of Prostate Cancer Study

2019-11-20 08:00:00 | Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

2019-11-20 07:58:12 | 5 Corporate Giants That Popped After Latest Earnings Release

2019-11-19 10:33:00 | Drug Legislation Likely to Dry Up Biotech Funding

2019-11-19 10:23:03 | Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

2019-11-19 05:00:00 | AbbVie- On the Cutting Edge

2019-11-18 08:00:00 | AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

2019-11-17 15:40:35 | AbbVie's Humira on Pace to Become Biggest Seller by 2024

2019-11-15 07:12:12 | Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

2019-11-15 06:41:11 | 4 Big Drugmakers to Bet on After a Great Earnings Season